A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.

NCT03507790 PHASE2 COMPLETED Results posted

This is a multi-center, randomized, double-blind, placebo-controlled, parallel group 36 week multicenter Phase 2 study of two doses of CT1812 in adults with mild to moderate Alzheimer's Disease (AD).

Details

Lead sponsor	Cognition Therapeutics
Phase	PHASE2
Status	COMPLETED
Enrolment	153
Start date	Wed Oct 10 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed May 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Mild to Moderate Alzheimer's Disease

Interventions

• CT1812
• Placebo

Countries

Netherlands, Australia, United States, Spain, Czechia